Please login to the form below

everolimus

This page shows the latest everolimus news and features for those working in and with pharma, biotech and healthcare.

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

In addition to the positive results for the Keytruda plus Lenvima combination, Merck and Eisai added that Lenvima plus everolimus also showed improvements in PFS and ORR compared to Sutent. ... However, Lenvima plus everolimus did not demonstrate an

Latest news

Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer

In a separate arm of the KEYNOTE-581 trial, the partner companies also evaluated Lenvima plus Novartis’ Afinitor (everolimus) in advanced RCC, with this combination also topping Sutent on PFS and
BMS unveils long-term results for Opdivo in kidney cancer

alive at this time-point compared to 18% of those treated only with the standard chemotherapy drug everolimus.
NICE nod for Lilly’s breast cancer drug Verzenio via CDF

NICE notes in its guidance that Verzenio and fulvestrant will be an option “where exemestane plus everolimus would be the most appropriate alternative treatment.”. ... On that point, Baroness Morgan said that as everolimus with exemestane is
Afinitor and Uptravi gain funding from NHS England

Around 70 people in England are currently prescribed everolimus for TSC-related kidney and brain tumours. ... NHS England estimates that a further 300 people in England will benefit from treatment with everolimus for TSC-related refractory epilepsy.
$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

First approved in 2015 for refractory thyroid cancer, Lenvima has subsequently been given the nod as a second-line treatment for renal cell carcinoma in combination with everolimus and has been

More from news
Approximately 8 fully matching, plus 66 partially matching documents found.

Latest from PMHub

Oncology drugs under AMNOG

patients the comparator was a different targeted therapy, Afinitor (everolimus), rather than Nexavar - although for cytokine-pretreated patients the trial comparator could be used.The G-BA still exercises its right

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Account Management: Competitive Salary Offered

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Principal Medical Writer: Varies on experience

PMHub

Add my company

Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....